SG Americas Securities LLC Sells 3,610 Shares of Regeneron Pharmaceuticals, Inc. $REGN

SG Americas Securities LLC trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 22.5% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 12,422 shares of the biopharmaceutical company’s stock after selling 3,610 shares during the period. SG Americas Securities LLC’s holdings in Regeneron Pharmaceuticals were worth $6,985,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in the stock. Salomon & Ludwin LLC acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth about $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $31,000. Traub Capital Management LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $38,000. Berbice Capital Management LLC grew its holdings in shares of Regeneron Pharmaceuticals by 300.0% during the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 60 shares in the last quarter. Finally, E Fund Management Hong Kong Co. Ltd. lifted its position in Regeneron Pharmaceuticals by 87.5% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 35 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $796.55 on Friday. The firm has a market cap of $83.72 billion, a price-to-earnings ratio of 19.07, a PEG ratio of 2.17 and a beta of 0.39. The company has a 50 day moving average of $738.12 and a 200-day moving average of $628.06. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. During the same period in the previous year, the business earned $12.46 EPS. Regeneron Pharmaceuticals’s revenue was up .9% compared to the same quarter last year. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, December 5th. Stockholders of record on Thursday, November 20th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.4%. The ex-dividend date was Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.43%.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Multiple analyst upgrades and higher targets — Bank of America and other firms raised ratings/targets this week, shifting consensus toward Buy and boosting investor confidence. Bank of America upgrade
• Positive Sentiment: Zacks moved REGN to a Zacks Rank #1 (Strong Buy), highlighting expectations for continued earnings outperformance. Zacks upgrade
• Positive Sentiment: Truist and other brokers raised price targets (Truist to $820), and aggregated analyst coverage (21‑analyst notes) points to a more favorable fundamental outlook — a catalyst for momentum buyers. 21‑analyst roundup
• Neutral Sentiment: Unusual options activity has picked up around REGN, signaling elevated trader interest and potential for amplified short‑term moves; direction is ambiguous. Unusual options activity
• Neutral Sentiment: Comparative analyst pieces (REGN vs peers) provide valuation context but are not immediate catalysts. REGN vs ILMN analysis
• Negative Sentiment: Insider selling: director Bonnie L. Bassler sold 1,500 shares at roughly $800 — a small dollar amount relative to market cap but sometimes triggers investor concern and short‑term profit‑taking. Insider sale SEC filing

Insider Activity

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of the stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the sale, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. This represents a 9.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bonnie L. Bassler sold 1,500 shares of the business’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the transaction, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This represents a 46.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 8,431 shares of company stock worth $5,733,521. 7.02% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on REGN shares. Cantor Fitzgerald increased their price objective on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th. Canaccord Genuity Group upped their target price on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a “buy” rating in a research note on Thursday, December 4th. Scotiabank increased their price target on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a research report on Monday, November 24th. Bank of America raised Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and lifted their price objective for the company from $627.00 to $860.00 in a report on Wednesday. Finally, Truist Financial increased their target price on Regeneron Pharmaceuticals from $798.00 to $820.00 and gave the stock a “buy” rating in a report on Thursday. Four equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $791.05.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.